Sarepta announced that the first patient has been dosed in Study SRP-9003-102. Also known as VOYAGENE, Study 9003-102 is a phase 1 study of SRP-9003 for the treatment of limb-girdle muscular dystrophy Type 2E/R4. VOYAGENE is a U.S.-only study enrolling ambulant patients aged 18 years or older and non-ambulant patients, ages 4-50 years, using clinical process SRP-9003 material.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRPT:
- Sarepta price target raised to $137 from $114 at Credit Suisse
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- UBS Says These 2 Stocks Offer Attractive Risk-Reward Right Now — Here’s Why
- Sarepta price target raised to $125 from $114 at Cowen
- Sarepta price target raised to $160 from $158 at Needham